Princeton based Sonnet Biotherapeutics [NASDAQ:SONN] has an interesting “Trojan Horse” approach that appears to have considerable promise with application in Covid – 19.
Sonnet has developed a unique platform that leverages several favorable biological properties of human serum Albumin. They have invented and developed an ingenious approach that converts endogenous albumin into a drug-loaded and/or immune stimulatory Trojan Horse that is taken up by unknowing cancer cells, leading to their destruction”.
To see the full Report visit the Research Reports tab or this link.